[go: up one dir, main page]

AU2001274239A1 - Neurotransmission disorders - Google Patents

Neurotransmission disorders

Info

Publication number
AU2001274239A1
AU2001274239A1 AU2001274239A AU7423901A AU2001274239A1 AU 2001274239 A1 AU2001274239 A1 AU 2001274239A1 AU 2001274239 A AU2001274239 A AU 2001274239A AU 7423901 A AU7423901 A AU 7423901A AU 2001274239 A1 AU2001274239 A1 AU 2001274239A1
Authority
AU
Australia
Prior art keywords
neurotransmission
bodily fluid
developmental disorders
mammal
musk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274239A
Inventor
Werner Hoch
Angela Vincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001274239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2001274239A1 publication Critical patent/AU2001274239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.
AU2001274239A 2000-06-16 2001-06-15 Neurotransmission disorders Abandoned AU2001274239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014878 2000-06-16
GBGB0014878.3A GB0014878D0 (en) 2000-06-16 2000-06-16 Neurotransmission disorders
PCT/GB2001/002661 WO2001096601A2 (en) 2000-06-16 2001-06-15 Neurotransmission disorders

Publications (1)

Publication Number Publication Date
AU2001274239A1 true AU2001274239A1 (en) 2001-12-24

Family

ID=9893880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274239A Abandoned AU2001274239A1 (en) 2000-06-16 2001-06-15 Neurotransmission disorders

Country Status (9)

Country Link
US (2) US7267820B2 (en)
EP (1) EP1327147B1 (en)
AT (1) ATE433575T1 (en)
AU (1) AU2001274239A1 (en)
CA (1) CA2455271C (en)
DE (1) DE60138958D1 (en)
ES (1) ES2327100T3 (en)
GB (1) GB0014878D0 (en)
WO (1) WO2001096601A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014878D0 (en) * 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders
EP2491389A4 (en) 2009-10-21 2013-07-31 Georgia Health Sciences University Res Inst Inc DETECTION AND TREATMENT OF NEUROTRANSMISSION DISORDERS ASSOCIATED WITH THE LRP4 RECEPTOR
GR1007341B (en) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Diagnostic assay
EP3128326B1 (en) * 2014-04-03 2018-03-14 Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Biomarker for diagnosis of aging or amyotrophia
US10093743B2 (en) * 2014-11-18 2018-10-09 Premkumar Christadoss Muscle specific tyrosine kinase-fluorophore conjugate compositions, kits and methods of using
EP3850015A1 (en) 2018-09-10 2021-07-21 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Musk activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814478A (en) * 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB0014878D0 (en) * 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders

Also Published As

Publication number Publication date
ES2327100T3 (en) 2009-10-26
WO2001096601A3 (en) 2002-03-28
US20080057524A1 (en) 2008-03-06
EP1327147A2 (en) 2003-07-16
CA2455271C (en) 2012-10-16
GB0014878D0 (en) 2000-08-09
DE60138958D1 (en) 2009-07-23
US20040082010A1 (en) 2004-04-29
WO2001096601A2 (en) 2001-12-20
CA2455271A1 (en) 2001-12-20
EP1327147B1 (en) 2009-06-10
ATE433575T1 (en) 2009-06-15
US7732147B2 (en) 2010-06-08
US7267820B2 (en) 2007-09-11

Similar Documents

Publication Publication Date Title
CA2250141A1 (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
BRPI0410261B8 (en) monoclonal antibody that specifically binds to probnp, methods for specific detection of probnp in vitro and for diagnosing heart failure in vitro, probnp measurement kit, and hybridoma cell line mab 1.21.3
SI1232392T1 (en) Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool
NO20006681D0 (en) Procedure for early diagnosis of carcinomas
SG112059A1 (en) Analytical sandwich test for determining nt-probnp
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
EP1381864A4 (en) Detection of candida
CA2214488A1 (en) Determination of cpsa
BR0113213A (en) Method for diagnosing an autoimmune disease, antibody, diagnostic composition, and antibody use
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
SE9600949D0 (en) Method of diagnosing a mycobacterial disease and immunoassay kit
AU2001274239A1 (en) Neurotransmission disorders
EP1214447B8 (en) Detecting the presence of the pyruvate kinase isoenzyme in feces
EP1072888A3 (en) Immunoassay method and reagent for HIV-1p24 antigen
AU2002233800A1 (en) Method and kit for predicting cancer
EP1245957A3 (en) Method of measuring ceruloplasmin concentration with enzyme-linked immunosorbent assay or dissociation-enhanced time-resolved fluoroimmunoassay in a blood spot, and Wilson's disease screening kit and method of diagnosing Wilson's disease
WO2001073437A3 (en) Antigen-specific enzyme-linked immunosorbent assay
EP1347298A3 (en) Immunoassay method, test strip for use therein, and immunoassay apparatus
BR0314207A (en) Immunoassays for the specific determination of scca isoforms
EP0364971A3 (en) Process for the detection of legionella antigens in body fluids and the like, as well as a test kit for performing the process
SE0100595D0 (en) Immunological detection of prostate diseases and prostatic-related diseases
KR870002453A (en) Method for manufacturing single antibody against prosome protein and detection of symptoms related to prosome and diagnosis of disease using the method
DE60228973D1 (en) Onsum
GB9725105D0 (en) Diagnosis of autoimmune adrenal disease
WO2002044723A3 (en) Method for diagnosing a predisposition of psychosis in a progeny